SAB Biotherapeutics Reports Third-Quarter 2026 Loss
SAB Biotherapeutics reported no revenue in the quarter, unchanged from a year earlier, and swung to a loss from income. The headline reports EPS of ($0.24).
SAB Biotherapeutics reported no revenue in the quarter, compared with none a year earlier, and swung to a loss from income. Higher research and development costs, including clinical-trial spending and related hiring to advance SAB-142 in the SAFEGUARD study, and increased general and administrative…